Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6
times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate
ophthalmic solution (0.1% HA) (one drop at a time, 6 times daily, 4 weeks topical
administration), is at least non-inferior in the change in fluorescein staining score, and is
superior in the change in Rose bengal score, in a multicenter, double-masked, parallel-group
comparison study. Safety profile will likewise be compared.